TTI Share Price Performance
Recent TTI News & Updates
No updates
Thiogenesis Therapeutics, Corp. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.083
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Thiogenesis Therapeutics, Corp. Competitors
About TTI
- Founded
- n/a
- Employees
- n/a
- CEO
- WebsiteView website
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.
Canadian Market Performance
- 7 Days: 0.2%
- 3 Months: 11.0%
- 1 Year: 18.3%
- Year to Date: 10.3%
Over the last 7 days, the market has remained flat, although notably the Industrials sector declined by 3.0%. As for the longer term, the market has risen 18% in the past 12 months. Looking forward, earnings are forecast to grow by 12% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading